SITE013-0285

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE013 (USA) · Dr. Clarke
consented 2023-02-09

AEs

Serious

Dropout signal

–

Adverse events

severe serious assessed

Grade 4 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-06-16 (study day 122); relationship: N; serious criteria: life-threatening

moderate assessed

Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-06-25 (study day 131); relationship: not assessed

mild assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-08-21 (study day 188); relationship: N

moderate assessed

Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-08-24 (study day 191); relationship: N

moderate assessed

Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-09-15 (study day 213); relationship: N

Data queries

No data queries.